The Oligonucleotides for CNS Summit is the must-attend forum for focused discussion allowing you to discover cutting-edge oligonucleotide research for neuromuscular & neurodegenerative diseases
With the global oligonucleotide therapeutics market forecasted to climb to a record value of 7 billion dollars in the next 3 years, a rapidly increasing volume of FDA approvals and major breakthroughs in novel nucleic acid delivery technologies, oligonucleotides are blazing a trail to being the hottest therapeutics of 2021 and beyond.
Built from extensive research with 25+ key stakeholders including Alnylam, Regeneron Pharmaceuticals and Eli Lilly, the digital Oligonucleotides for CNS Summit is the premier scientific platform for industry experts to discover how they can optimize the therapeutic opportunity of ASOs, RNAi & mRNA, from target specific delivery to the clinic, & maximize therapeutic benefit in CNS & muscle disorders.
Access the Full Event Guide for all of the information you need on the event:
Joining the expert speaker faculty:
- Keith Foster, Chief Scientific Officer, Sutura Therapeutics
- Romesh Subramanian, Chief Scientific Officer, Dyne Therapeutics
- Susan Rosenbaum, Founder, Chairman & CEO, Lauren Sciences
- Michel Khrestchatisky, Chief Executive Officer, Vect Horus
- Anthony Saleh, Chief Executive Officer, miRecule
- Eva Chin, Chief Development Officer, NMD Pharma
- Tasuku Kitada, Co-founder, Director, President, & Head of R&D, Strand Therapeutics
- Ken Rhodes, Senior Vice president, Therapeutics Discovery, Wave Life Sciences
- Robert Shaffer, Founder, Enable Therapeutics
- Nathalie Goemans, Head of the Neuromuscular Reference Centre for Children, The University Hospitals Leuven
- Ken Loveday, Principal Investigator, Toxicology, Biogen
- Kirk Brown, CNS Early Development, Alnylam Pharmaceuticals
- Jimmy Weterings, Principal Scientist, Oligonucleotide Chemistry Team, AstraZeneca
- Andres Montefeltro, Oligonucleotide Expert, Micure Therapeutics
- Anna M. Krichevsky, Ph.D., Associate Professor of Neurology, Harvard Medical School
Committed to providing you with the latest scientific advances, data and key lessons learned over the past year, this pioneering meeting will answer your burning questions on the toughest issues in the field, including:
- Understanding & overcoming delivery challenges to optimize RNA therapeutics in the CNS alongside Dyne Therapeutics
- Successfully translating pre-clinical success into clinical success to upgrade your therapeutic efficacy with Alnylam Pharmaceuticals & Biogen
- Manipulating your therapeutics oligonucleotide chemistry to minimize toxicity and maximize potency by AstraZeneca
- Streamlining extra-hepatic delivery for targeted delivery of oligonucleotides with Vect-Horus
- Learning how to harness oligonucleotide delivery devices for CNS & Muscle Disorders with miRecule
- Discovering how to utilize oligonucleotide therapeutics to treat rare diseases of the CNS with Wave Life Sciences
The Oligonucleotides for CNS Summit is the must-attend forum for focused discussion allowing you to discover cutting-edge oligonucleotide research for neuromuscular & neurodegenerative diseases, cement relationships with fellow industry pioneers and optimize oligos to achieve life-changing therapeutic benefits, which is why over 40 companies are already signed up to attend, including:
Alnylam Pharmaceuticals Arrowhead Pharmaceuticals Inc., Arthex Biotech SL, Astellas Pharma Inc, AstraZeneca, Biogen Idec, Biologie Servier, CAMP4 Therapeutics, Cerebral Therapeutics LLC, ChemGenes Corporation, Denali Therapeutics Inc., Dicerna Pharmaceuticals Inc., Dyne Therapeutics, Enable, Entrada Therapeutics, Exicure, Leiden University, miCure Therapeutics Ltd., MiRecule Inc., Neumirna, NMD Pharma, Otsuka Pharmaceutical, Q-State Biosciences, Quark Pharmaceuticals, Regulus Therapeutics, Roche, Servier, Strand Therapeutics Inc., Sutura Therapeutics, Triplet Therapeutics, UMass Medical School, University Of Leuven, University of Southern Denmark, Wave Life Sciences
Don’t miss out, secure your place alongside them here: www.oligonucleotides-cns.com/take-part/register/